[EDGAR] Zimmer Holdings Inc (NYSE:ZMH)(TREND ANALYSIS) issued a press release announcing that it has finalized agreements with buyers to divest certain assets in the United States in furtherance of its proposed acquisition of Biomet, Inc. (“Biomet”). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Zimmer Holdings Inc (NYSE:ZMH) stock is currently trading 7.91% below its 52-week-high, 18.44% above its 52-week-low. The 1-year stock price history is in the range of $94.73 – $121.84. Zimmer Holdings Inc (ZMH) has a price to earnings ratio of 28.62 versus Healthcare sector average of 26.66. ZMH stock price has underperformed the S&P 500 by 3.7%. The Medical Products company is currently valued at $19.12 billion and its share price closed the last trading session at $112.2. The stock has a 50-day moving average of $113.37 and a 200-day moving average of $115.53.
Zimmer Holdings Inc (ZMH) current short interest stands at 4.13 million shares. It has decreased by 13% from the same period of last month. Around 3% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.03 million shares, the number of days required to cover the short positions stand at 4.1 days.
The company is expected to announce next quarter earnings on July 23, at consensus estimate of $1.58. Zimmer Holdings Inc (ZMH) reported last quarter earnings on April 30. The Medical Products company announced earnings per share of $1.58 against a consensus Street estimate of $1.54, beating the average estimate by $0.04. This corresponds to an increase of $0.04 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently twenty-four analysts that cover Zimmer Holdings Inc stock. Of those twenty-four, nineteen have a Buy rating, five have a Hold rating. On a consensus basis this yields to a Buy rating. The consensus target price stands at $128.
A recent analyst activity consisted of Jefferies reiterating their Buy stance on May 11. Jefferies decreased price target from $131 to $127. This corresponds to a 13.19% upside from the last closing price. On the date of report, the stock closed at $112.96.
Barclays reiterated their Overweight stance on May 1, and decreased their price target from $135 to $130. This corresponds to a 15.86% upside from the last closing price. On the date of report, the stock closed at $110.21.
Zimmer Holdings, Inc. designs, develops, manufactures, and markets orthopedic and dental reconstructive implants, spinal implants, trauma products and related surgical products. The Company also provides other healthcare related services. Zimmer markets its products in the United States and other countries around the world.